Juanita Lopez

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.4K citations · Full text

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul et al. · Journal of Clinical Oncology · 2018 · 965 citations

The Ripoptosome, a Signaling Platform that Assembles in Response to Genotoxic Stress and Loss of IAPs

Tencho Tenev, Katiuscia Bianchi, Maurice Darding et al. · Molecular Cell · 2011 · 805 citations · Full text

Genotoxic Stress, Systems Biology, Signal Transduction +9

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud et al. · Journal of Clinical Oncology · 2017 · 504 citations

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

Evan Alley, Juanita Lopez, Armando Santoro et al. · The Lancet Oncology · 2017 · 489 citations

Malignant Pleural Mesothelioma, Medicine, Clinical Safety +6